Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec): A case report and review of the literature

Miguel A. Park, Gerald W. Volcheck, Juan C. Guarderas

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthemfrom imatinib mesylate and a review of the literature.

Original languageEnglish (US)
Pages (from-to)345-347
Number of pages3
JournalAllergy and Asthma Proceedings
Volume25
Issue number5
StatePublished - Sep 1 2004

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Successful progressive challenge after a cutaneous reaction to imatinib mesylate (gleevec): A case report and review of the literature'. Together they form a unique fingerprint.

Cite this